1. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Issue 3 (19th March 2019) Authors: Lukey, Pauline T.; Harrison, Stephen A.; Yang, Shuying; Man, Yim; Holman, Beverley F.; Rashidnasab, Alaleh; Azzopardi, Gabrielle; Grayer, Michael; Simpson, Juliet K.; Bareille, Philippe; Paul, Lyn; Woodcock, Hannah V.; Toshner, Richard; Saunders, Peter; Molyneaux, Philip L.; Thielemans, Kris... Journal: European respiratory journal Issue: Volume 53:Issue 3(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Issue 8 (21st April 2016) Authors: Mercer, Paul F; Woodcock, Hannah V; Eley, Jessica D; Platé, Manuela; Sulikowski, Michal G; Durrenberger, Pascal F; Franklin, Linda; Nanthakumar, Carmel B; Man, Yim; Genovese, Federica; McAnulty, Robin J; Yang, Shuying; Maher, Toby M; Nicholson, Andrew G; Blanchard, Andy D; Marshall, Richard P; Lu... Journal: Thorax Issue: Volume 71:Issue 8(2016) Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗